Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00494442 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00494442 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 58 participants.
The verdict
NCT00494442, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
Interventions
- DRUG KU-0059436 (AZD2281)(PARP inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-06-11 |
| Est. Completion | 2017-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00494442
The ClinicalTrials.gov registry entry for NCT00494442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KU-0059436 (AZD2281)(PARP inhibitor) is the first listed.
NCT00494442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00494442 about?
NCT00494442 is a clinical study titled "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer". The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
What is the current status of trial NCT00494442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2007-06-11. Estimated completion is 2017-07-20.
What interventions are being tested in trial NCT00494442?
The interventions under investigation include: KU-0059436 (AZD2281)(PARP inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00494442?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.